HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Enrico Garattini Selected Research

Retinoids

7/2014Retinoids and breast cancer: from basic studies to the clinic and back again.
1/2012Retinoids and breast cancer: new clues to increase their activity and selectivity.
2/2011Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets.
9/2008Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity.
1/2007Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations.
1/2007Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents.
10/2004Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.
11/2002Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Enrico Garattini Research Topics

Disease

9Neoplasms (Cancer)
07/2015 - 01/2004
5Breast Neoplasms (Breast Cancer)
07/2015 - 01/2012
4Carcinoma (Carcinomatosis)
07/2015 - 04/2002
4Myeloid Leukemia (Leukemia, Myelocytic)
11/2010 - 11/2002
3Acute Promyelocytic Leukemia
02/2009 - 11/2002
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2009 - 05/2006
3Leukemia
01/2007 - 10/2004
3Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
10/2004 - 11/2002
1Neuroblastoma
05/2012
1Hematologic Neoplasms (Hematological Malignancy)
01/2012
1Chromosome Aberrations (Chromosome Abnormalities)
09/2008
1Ataxia (Dyssynergia)
09/2008
1Teratocarcinoma
09/2006
1Hepatocellular Carcinoma (Hepatoma)
02/2005

Drug/Important Bio-Agent (IBA)

12Tretinoin (Retinoic Acid)FDA LinkGeneric
07/2015 - 11/2002
8RetinoidsIBA
07/2014 - 11/2002
2MicroRNAs (MicroRNA)IBA
05/2015 - 02/2011
2Aldehyde OxidaseIBA
08/2011 - 02/2005
2Retinoic Acid Receptors (Retinoic Acid Receptor)IBA
02/2009 - 10/2004
2promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA
02/2009 - 05/2006
23- (4'- hydroxy- 3'- adamantylbiphenyl- 4- yl)acrylic acidIBA
09/2006 - 01/2004
2retinoic acid receptor gammaIBA
09/2006 - 04/2002
2retinoic acid receptor alphaIBA
10/2004 - 11/2002
1Transforming Growth Factors (Transforming Growth Factor)IBA
07/2015
1Phenobarbital (Luminal)FDA Link
07/2015
1Carbon MonoxideIBA
05/2015
1lapatinib (GW572016)FDA Link
05/2015
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
07/2014
1First StepIBA
05/2012
1Estrogens (Estrogen)FDA Link
02/2011
1Histones (Histone)IBA
11/2010
1TubulinIBA
11/2010
1Peptidylprolyl Isomerase (Prolyl Isomerase)IBA
02/2009
1Protein Kinases (Protein Kinase)IBA
09/2008
11,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
09/2008
1DNA (Deoxyribonucleic Acid)IBA
09/2008
1naphthaleneIBA
09/2006
1Cisplatin (Platino)FDA LinkGeneric
07/2005
1Tetrachlorodibenzodioxin (TCDD)IBA
02/2005
1Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
10/2004
1piclamilastIBA
10/2004
1CalciumIBA
01/2004
1ST 1346IBA
11/2002
1Paclitaxel (Taxol)FDA LinkGeneric
04/2002

Therapy/Procedure

2Chemoprevention
07/2015 - 07/2014
2Transplants (Transplant)
01/2004 - 11/2002
1Aftercare (After-Treatment)
09/2006